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Abstract
The application of scaffolds in bone tissue engineering 
often comes along with side effects such as poor integrity, 
low regeneration rates of bone tissue with inadequate 
functionality, and, in case of non-degradable implants, 
the necessity of a second removal surgery after therapy. 
In this study, we coated a bioresorbable FDA-approved 
poly-(ε-caprolactone)-scaffold for bone regeneration with 
a poly-(D,L-lactide) layer containing copolymer-protected 
gene vectors to locally provide bone morphogenetic 
protein-2 (BMP-2). Results show that the presence of such 
gene vectors did not affect the distribution and attachment 
of seeded cells on gene-activated surfaces. BMP-2 was 
released into cell culture supernatants and furthermore 
detected in homogenised scaffolds. Increased amounts 
of osteoblastic markers, such as osteocalcin, osteopontin 
and the activity of alkaline phosphatase, in gene-activated 
scaffolds in vitro suggest a transdifferentiation of myoblastic 
C2C12 cells into the osteoblastic phenotype. With this study 
we present a new technology to bioactivate implant surfaces 
with non-viral gene vectors. This tool allows the stimulation 
of tissue regeneration by a local release of therapeutic 
proteins in vivo.
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Introduction
Delayed healing, or non-union of bones, after traumatic 
events have tremendous impact on patients and health 
care systems (Donaldson et al., 2008; Garrison et 
al., 2010). Autologous transplantation of cortical and 
cancellous bone from iliac crest still remains the gold 
standard for the therapy of delayed or non-healing bone 
defects (Giannoudis et al., 2005; Lee and Shin, 2007). 
Although the simultaneous availability of osteoinductive 
factors, bone forming cells and osteoconductive matrices 
is beneficial, donor morbidity and limited availability 
remain drawbacks. Artificial bone substitutes present 
an alternative and should ideally provide osteogenicity, 
osteoinductivity and osteoconductivity, beside implant 
integrity (Bueno and Glowacki, 2009). The local 
regulation of bone regeneration underlies a distinct 
interaction of growth factors, hormones and cytokines 
with bone cells.
  Bone morphogenetic proteins (BMPs) are crucial 
key substances for fracture healing (Barnes et al., 1999). 
BMPs are multifunctional proteins and are members of 
the transforming growth factor-ß (TGF-ß) superfamily. In 
1965, Urist observed their ability to initiate ectopic bone 
formation (Urist, 1965). The osteoinductive potential of 
BMPs in vivo has been reported in many animal studies 
and clinical trials (Bilic et al., 2006; Chen et al., 2004; 
Dimar et al., 2006; Gelse et al., 2003; Jones et al., 2006; 
Kirker-Head, 2000; Lee and Shin, 2007; Nakagawa 
et al., 2001; Okubo et al., 2000; Pelttari et al., 2006; 
Steinhardt et al., 2008). Only BMP-2 and BMP-7 are 
approved by the Food and Drug Administration (FDA) 
for clinical use to promote bone regeneration (Bessa et 
al., 2008a; Bessa et al., 2008b; Kanakaris et al., 2008). 
BMP-2 is indispensable for efficient fracture healing 
in bone (Tsuji et al., 2006). Different materials have 
been investigated in combination with recombinant 
osteoinductive biomolecules (Giannoudis et al., 2005). 
The half-life of recombinant human BMP-2 (rhBMP-2) 
is about 20-30 minutes (Valentin-Opran et al., 2002). 
Therefore, the application of these molecules to moderate 
a bone healing process of weeks or months (Marks and 
Popoff, 1988) has limited operational capacity. Recent 
methods to treat critical bone defects with implants are 
not satisfying and new innovative concepts deserve to be 
studied to regenerate bone with complete functionality.
  Gene therapy allows local expression of specific 
growth factors. Viral gene vectors have been useful in 
tissue engineering (Margolis et al., 2000; Margolis et al., 
2004; Mulder et al., 2009; Zhang and Godbey, 2006), but 
their use in humans is limited due to their difficult clinical 442 www.ecmjournal.org
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translation, predominantly with respect to costs, efficacy 
and regulatory constraints. In contrast, non-viral vectors 
allow avoiding most safety concerns associated with 
viral vectors and are certainly less demanding concerning 
manufacturing, handling and costs. Their major limitation 
remains efficacy.
  Here, we present a new technology to genetically 
activate implant surfaces to produce osteoinductive 
molecules with copolymer-protected gene vectors 
(COPROGs) encoding BMP-2 (Finsinger et al., 2000; 
Honig et al., 2010). Positively charged polyethylenimine 
(PEI)/DNA polyplexes are coated with an anionic 
polyethylene glycol copolymer, hence generating 
COPROGs, which prevents salt- and serum albumin-
induced aggregation and reduces, or abolishes, complement 
activation, known from unshielded PEI/DNA polyplexes as 
described before (Finsinger et al., 2000). A commercially 
available poly-(ε-caprolactone) (PCL) biomaterial was 
coated with a COPROG-containing poly-(D,L-lactide) 
(PDLLA) layer. The use of such COPROG-PDLLA-
coatings for biomechanically stable, but degradable 
scaffolds, has several advantages. Both polymers, PCL and 
PDLLA, are aliphatic polyesters, which underlie mainly 
hydrolytic degradation in vivo and in vitro (Gunatillake and 
Adhikari, 2003; Middleton and Tipton, 2000; Wintermantel 
and Ha, 2009). The used PCL-scaffold (Osteomesh®) is 
manufactured by fused deposition modelling (FDM) and 
possesses an interconnective pore network, biocompatibility 
and mechanical strength (Causa et al., 2006; Hutmacher et 
al., 2001). This scaffold has been coated with fibrin glue 
containing rhBMP-2 to stimulate bone regeneration, but 
this approach only led to short release of BMP-2 in vitro 
(Rai et al., 2005). Another study presented positive effects 
of rhBMP-2-PDLLA-coating of titanium implants for bone 
healing and biomechanical strength of regenerated tissue 
(Schmidmaier et al., 2002). Moreover, a recently published 
article describes the feasibility of a COPROG/PDLLA-
coating on non-degradable titanium implants in vitro (Kolk 
et al., 2011). The aim of this study was to evaluate whether 
the release of BMP-2 from BMP-2-COPROG-activated 
PDLLA-coated PCL-scaffolds can initiate differentiation 
of relevant cells and therefore enhance bone healing and 
integrity of such biodegradable implants.
Materials and Methods
Plasmids
The plasmid pMetLuccontrol, coding for Metridia 
luciferase as a secreted reporter protein, was purchased 
from Clontech Laboratories (Mountain View, CA, USA), 
expanded and purified by PlasmidFactory GmbH & Co. 
(Bielefeld, Germany).
Preparation of vector formulation
Plasmid and branched PEI (25 kDa; Sigma-Aldrich, 
Deisenhofen, Germany) were mixed in water at an N/P 
ratio of 8. After 15 min incubation, the resulting PEI/
DNA complex was added to 2 charge equivalents of 
protective copolymer P6YE5C (synthesis as described 
before (Finsinger et al., 2000)) in water and incubated 
for 30 min at room temperature. All components were 
prepared in equal volumes before mixing as previously 
described (Finsinger et al., 2000), and COPROG solutions 
were lyophilised (Alpha 1-2 LD plus; Christ, Osterode, 
Germany). Lyophilised COPROGs were homogeneously 
suspended in a solution of 150 mg PDLLA/mL ethylacetate 
(EtOAc) with the use of a Teflon® pestle (Schütt 
Labortechnik, Göttingen, Germany).
PDLLA-coating of poly-(ε-caprolactone) scaffolds
Osteomesh® (Osteopore, Singapore) was cut into disk-
shaped specimens with a 6 mm diameter punch (Acupunch; 
Xiomedics, Unterhaching, Germany). 50 µL COPROG/
PDLLA/EtOAc-suspension containing 7.5 mg PDLLA 
(Resomer® R203H; Boehringer Ingelheim, Ingelheim, 
Germany) and indicated amounts of COPROGs were 
distributed on scaffold surfaces. Control scaffolds were 
coated solely with a PDLLA/EtOAc-suspension containing 
7.5 mg PDLLA. After evaporation of EtOAc, polymer 
films remained and scaffolds were stored under vacuum 
overnight.
Cell culture and transfection
C2C12 mouse myoblasts (ATCC# CRL-1772) were grown 
at 37 °C in an atmosphere of 5 % CO2 in Dulbecco’s 
Modified Eagle Medium (DMEM; Biochrom AG, Berlin, 
Germany) supplemented with 10 % foetal calf serum 
(FCS; PAN-Biotech, Aidenbach, Germany) and penicillin/
streptomycin (Biochrom AG, Berlin, Germany). 50 µL 
medium containing 100,000 cells/scaffold was inoculated 
onto the dried scaffold. In order to ensure cell attachment 
to the scaffold an incubation step of 2 h was performed 
in culture conditions. Afterwards additional medium was 
added. After 24 h, scaffolds were moved into 48 well 
plates containing fresh medium and culture medium was 
replaced every 2 d.
Scanning electron microscopy
Scanning electron microscopy (SEM) was used to 
characterise scaffold structure. Samples were fixed 
with 3 % glutaraldehyde (Sigma-Aldrich, Deisenhofen, 
Germany), dehydrated, dried, and sputtered with gold (Bal-
Tec SCD005, 30 mA, 240 s). SEM was carried out using a 
JEOL-SEM JSM-5400 (Eching, Germany) in Hi-Vac mode 
by applying an acceleration voltage of 5 kV and detecting 
secondary electrons for imaging.
Metridia luciferase bioluminescence assay
Cell culture supernatant was collected every 48 h, being 
completely replaced and deep frozen (-80 °C) until final 
measurements. For quantification, 50 µL supernatant was 
mixed, in black 96-well plates (Corning, Tewksbury, MA, 
USA), with 20 μL 0.05 mM Coelenterazine (Synchem, 
Felsberg, Germany) and measured using a luminescence 
counter (Top Count; Canberra Packard, Dreieich, 
Germany).
Quantification of metabolic activity – MTT assay
15 d after cell seeding, scaffolds were incubated for 1 h 
under culture conditions in phosphate-buffered saline 
(PBS) containing 500 µg/mL of 3-(4.5-dimethyl-2-443 www.ecmjournal.org
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thiazolyl)-2.5-diphenyl-2Htetrazolium bromide (MTT; 
Sigma-Aldrich, Deisenhofen, Germany). Next, MTT 
solution was removed and scaffolds were washed with PBS. 
Aferwards, scaffolds were incubated in 500 µL dimethyl 
sulphoxide (DMSO; Sigma-Aldrich, Deisenhofen, 
Germany) until all formazan blue was extracted. Finally, 
absorbance at 560 nm was measured.
Quantification of BMP-2
BMP-2 concentrations in medium or protein extracts 
were measured by ELISA according to manufacturer’s 
instructions (BMP-2 Quantikine ELISA Kit; R&D 
Systems, Minneapolis, USA). The tissue samples were 
homogenised with a Mini-beadbeater™ (Biospec Products 
Inc.; Bartlesville, OK, USA; 1 × 20 s pulses) in 2 mL 
screw-cap tubes (VWR Scientific Products, West Chester, 
PA, USA) containing 1 g zirconia beads (2.5 mm; Biospec 
Products Inc., Bartlesville, OK, USA) and 0.5 mL 2 M 
guanidine-HCl. Samples were kept on ice during the whole 
procedure. After centrifugation (7600 RPM for 5 min at 
4 °C), 100 μL of the supernatant was analysed.
Analysis of osteoblastic markers
To determine the biological activity of manufactured 
BMP-2, the production of osteocalcin, osteopontin and 
the activity of alkaline phosphatase of C2C12 cells was 
analysed. Osteocalcin was quantified in 100 µL cell culture 
supernatants by ELISA according to manufacturer’s 
instructions (Mouse Osteocalcin ELISA Kit BT-470; 
Biomedical Technologies Inc., Stoughton, MA, USA). 
Osteocalcin, osteopontin and the activity of alkaline 
phosphatase were analysed in 100 µL homogenised 
scaffolds (Mouse Osteopontin ELISA Kit E0899Mu; 
USCN Lifescience Inc., Wuhan, China and p-Nitrophenyl 
Phosphatase Liquid Systems; Sigma-Aldrich, Deisenhofen, 
Germany). All parameters are shown relative to the total 
amount of protein in samples, detected by Pierce® BCA 
Protein Assay Kits (Fisher Scientific, Schwerte, Germany).
Statistical analysis
All assays were repeated in at least 3 independent 
experiments. Statistical analysis with the comparison of 
only two groups was performed using Student’s t-test. For 
the comparison of three or more groups, one way ANOVA 
was performed followed by post-hoc analyses. Data are 
expressed as mean ± standard error of the mean.
Results
Surface characterisation of PDLLA-coated PCL 
scaffolds
The SEM analysis of surface conditions of PDLLA-
coated and uncoated PCL scaffolds showed a very smooth 
surface after the coating procedure and pores were 
completely filled with PDLLA (Figs. 1A and 1B). 5 d after 
seeding C2C12 cells onto PDLLA-coated PCL, a regular 
distribution of adherent cells was observed. Cells showed 
usual morphology for this cell type (Fig. 1C; white arrows). 
Irregularities in PDLLA coating demonstrate beginning 
degradation of PDLLA after 5 d of cell culture (Fig. 1C; 
black arrows).
Optimisation of vector dose for efficient gene transfer
Different amounts of COPROGs (with respect to DNA 
content) were immobilised on PCL scaffolds in PDLLA/
EtOAc suspension, and after evaporation of the organic 
solvent C2C12 cells were seeded. Release kinetics of the 
secreted reporter protein Metridia luciferase (Fig. 2A) 
Fig. 1. Scanning electron microscopy pictures of native (A), PDLLA-coated PCL without cells (B), and 5 d after 
seeding of C2C12 cells onto PDLLA-coated PCL (C). Scale bar represents 500 µm in upper panel and 50 µm in 
lower panel.444 www.ecmjournal.org
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and metabolic activity of seeded cells (Fig. 2B) were 
analysed relative to gene vector dose. Metridia luciferase 
was detected in cell culture supernatants of 15, 30, 45 
and 60 µg pDNA/scaffold. Furthermore, 30 µg pDNA/
scaffold could facilitate a prolonged reporter protein release 
for at least 9 d. A further increase of vector dose did not 
lead to increased protein expression (Fig. 2A). Metabolic 
activities of cells growing on control scaffolds and 15, 
30 µg pDNA/scaffold did not show differences, whereas 
it was significantly decreased for 45 and 60 µg pDNA/
scaffold (Fig. 2B).
Expression of growth factor BMP-2
After verifying an optimal dose of 30 µg pDNA (relative 
to COPROGs)/7.5 mg PDLLA /50 µL EtOAc condition 
for efficient gene transfer in vitro, BMP-2-COPROG-
PDLLA-coated PCL scaffolds were examined for their 
ability to release BMP-2 (Fig. 3). BMP-2-COPROGs 
were suspended in a solution of PDLLA in EtOAc, PCL 
scaffolds were coated, and the release of BMP-2 into 
culture supernatants was analysed (Fig. 3A). An initial 
BMP-2 release at day 1 and 3 was detected. BMP-2 in 
homogenised scaffolds was analysed after 17 d cell culture 
Fig. 2. Optimisation of gene vector dose. (A) Different amounts of COPROGs (with respect to DNA content: 15, 30, 
45 and 60 µg) encoding reporter protein Metridia luciferase were suspended in 7.5 mg PDLLA/50 µL EtOAc and 
protein release was observed in cell culture supernatants. Day 1 shows highest reporter protein concentration for 15 
and 30 µg pDNA. 30 µg pDNA showed the highest amount of Metridia luciferase release for up to 9 d. A further 
increase of vector dose was not followed by increasing protein release. (B) 15 d after cell seeding metabolic activity 
was determined with MTT assay. No differences in metabolic activity could be detected between control scaffolds 
and 15 and 30 µg pDNA, but cells growing on 45 and 60 µg pDNA showed significantly reduced metabolic activity 
(p < 0.05).
Fig. 3. BMP-2 expression. (A) C2C12 cells were seeded on control or BMP-2-COPROG-activated scaffolds, and 
BMP-2 expression was analysed. BMP-2 release could be detected initially at day 1 and day 3 and also on day 15 
in cell culture supernatants from BMP-2-COPROG-activated scaffolds. (B) After 17 d, scaffolds were homogenised 
and showed 8 fold increased BMP-2-content in COPROG-activated scaffolds compared to control (p = 0.067).445 www.ecmjournal.org
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(Fig. 3B). After homogenisation of scaffolds in PBS (data 
not shown) no BMP-2 was detectable. After homogenising 
in 2 M guanidine-HCl an average of 12 pg BMP-2/mg 
total protein was detected in BMP-2-COPROG-activated 
scaffolds. This means an 8 fold increase to controls (p = 
0.067).
Detection of transdifferentiation markers
To determine, if the produced BMP-2 has a functional 
activity, osteocalcin production (Fig. 4) and osteopontin 
production and the activity of alkaline phosphatase 
of C2C12 cells (Fig. 5) were determined. A release of 
osteocalcin by C2C12 cells growing on gene-activated 
scaffold surfaces was observed from day 5 on, with 
exponentially increasing kinetics (Fig. 4A). The analysis 
of homogenised scaffolds after 17 d of cell culture shows a 
3.5 fold increased amount of osteocalcin relative to controls 
(Fig. 4B). The activity of alkaline phosphatase of C2C12 
cells growing on gene-activated surfaces (Fig. 5A) and the 
amount of osteopontin (Fig. 5B) is significantly increased 
after 17 d cell culture (p < 0.05).
Discussion
The challenge of matrix-mediated therapy for non-healing 
or delayed healing of bone defects is allocation of adequate 
integrity at the defect site (Kanczler and Oreffo, 2008), 
along with delivering osteoconductive or -inductive 
properties, mechanical stability and load capacity. 
Different studies documented an improved bone healing 
after application of recombinant BMPs on PDLLA-coated 
titanium implants (Schmidmaier et al., 2002; Wildemann et 
al., 2004). The duration of fracture healing, under natural 
Fig. 4. Quantification of osteocalcin. (A) C2C12 cells were seeded on control or BMP-2-COPROG-activated scaffolds, 
and osteocalcin expression was analysed. Osteocalcin release showed exponential increasing values from day 3 on 
in cell culture supernatants from BMP-2-COPROG-activated scaffolds. (B) After 17 d, quantification of osteocalcin 
in homogenised scaffolds showed an increase in COPROG-activated scaffolds compared to control.
Fig. 5. Analysis of homogenised scaffolds. 17 d after seeding of C2C12 cells on BMP-2-COPROG-PDLLA-
coated PCL-scaffolds and control scaffolds the activity of alkaline phosphatase (A) and osteopontin-content (B) in 
homogenised scaffolds were analysed. Both parameters are significantly increased relative to controls (p < 0.05).446 www.ecmjournal.org
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conditions, lasts about 20 weeks (Garrison et al., 2010). 
Therefore, a prolonged supply of osteoinductive molecules 
is indispensable. Under consideration of systemic side 
effects, recombinant growth factors are not sufficient.
  In this study the properties of a non-viral gene-activated 
surface coating of a mechanically stable, but biodegradable, 
material have been examined. The release of therapeutic 
molecules from COPROG-PDLLA-coatings of PCL-
scaffolds presents an increased osteoinductive potential of 
such bioactive surfaces. The very smooth coated PDLLA-
surface of the PCL-implant (Fig.1B) did not affect the 
distribution, attachment or morphology of cells (Fig.1C, 
white arrows). After 5 d under cell culture conditions a 
beginning degradation of the PDLLA-layer was indicated 
(Fig. 1C, black arrows). To determine optimal gene transfer 
conditions comprising highest possible gene expression 
without cell toxicity, the relation of reporter gene 
expression and metabolic cell activity was determined. 
An increase of vector dose (with respect to DNA content) 
over 30 µg pDNA/7.5 mg PDLLA/6 mm scaffold did not 
lead to further enhancement of protein expression (Fig. 
2A) but to decreased metabolic activity of cells (Fig. 2B). 
Therefore this vector dose was considered to be optimal 
for further experiments.
  BMP-2 plays a key role in the regeneration of bone 
and stimulates the proliferation and differentiation of 
progenitor cells to osteoblasts. Here, the production 
of BMP-2 after seeding C2C12 cells on BMP-2-
COPROG-PDLLA-coatings and the amount of BMP-2 in 
homogenised scaffolds was studied. The release kinetics 
of BMP-2 and reporter gene is similar (Fig. 2A and 3A). 
Initially, days 1 and 3 showed a distinct BMP-2 release to 
cell culture supernatants (Fig. 3A). After homogenisation 
of scaffolds in PBS, no BMP-2 was detectable (data not 
shown), but the homogenisation in 2 M guanidine-HCl 
resulted in an 8 fold increase in BMP-2 content relative to 
controls. Summarising this and the fact that after 5 d just 
minimal BMP-2 levels could be detected in cell culture 
supernatants (Fig. 3A) points to strong interaction of 
BMP-2 to the implant material. This observation suggests 
only local supply of BMP-2 at the implant side and can be 
advantageous in terms of avoiding systemic distribution 
and side effects of growth factors. BMP-2 release on day 1 
and 3 was followed by an exponentially increasing release 
of osteocalcin (Fig. 3A and 4A). C2C12 cells showed a 
significant increased alkaline phosphatase activity on 
BMP-2-COPROG-activated scaffolds relative to controls 
after 17 d of cell culture (Fig. 5A). The quantification of 
osteocalcin and osteopontin in homogenised scaffolds 
showed a distinct increase relative to controls (Fig. 4B and 
5B). This suggests a transdifferentiation of C2C12 cells 
into the osteoblastic phenotype with BMP-2-COPROG-
PDLLA-coated PCL scaffolds.
  This technology combines the osteoinductive effects of 
a BMP-2-COPROG-PDLLA coating with a mechanically 
stable, but biodegradable, PCL-scaffold. A translation to 
in vivo conditions is under further investigation. Here, we 
suggest that the stimulation of osteogenic differentiation 
of relevant cells in vivo can enhance the integrity of such 
implants in the defect area and improve mechanical loading 
and functionality of the regenerating tissue (Mavrogenis 
et al., 2009). This technology offers the opportunity to 
provide biodegradable or non-degradable, porous or 
non-porous scaffolds with a gene-activated COPROG-
PDLLA-coating, which according to the degradation rate 
of coating-polymers (here PDLLA) lead to a controlled 
release of therapeutic molecules after transfection of cells 
at the implant site and, therefore, can lead to an optimised 
treatment of bone defects.
Conclusion
This study presents a pioneering technology to prepare 
bioactive implant surfaces in a one-step procedure with a 
relatively easy clinical translation, as it can be performed 
under GMP standards, generating a stable product that is 
simple to implement in clinical settings. This innovative 
approach allows a local release of bioactive molecules 
and offers a cell-free and virus-free scaffold bioactivation 
strategy for degradable and non-degradable materials. 
Although in vitro results are promising, further studies 
should be performed to determine the optimal functionality 
of this approach in vivo.
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Discussion with Reviewers
Reviewer II: What is the explanation of the “optimal” 
vector dose of 30 µg pDNA/7.5 mg PDLLA per scaffold? 
Why does a higher vector dose lead to a reduced metabolic 
activity of the cells?
Authors: The reduced metabolic activity of cells observed 
in this study is most probably not directly related to the 
amount of pDNA, but to one of the other two components 
of this gene vector. The used gene vector (COPROG) is 
composed of three components: pDNA, polyethylenimine 
(PEI) and the PEG-Copolymer P6YE5C. Polyethylenimine 
is a polycationic molecule and can lead to aggregation 
with negatively charged cell components and therefore, 
depending on its dose, affect the metabolic activity of 
cells. As a consequence there is a therapeutic window for 
the use of gene vectors. Here the desired gene vector dose 
comprises high gene transfer efficiency and no reduction 
of metabolic cell activity. In our settings, results indicated 
a vector dose containing 30 µg plasmid DNA (pDNA) and 
7.5 mg PDLLA/ scaffold to be the highest possible dose 
of gene vector without affecting the metabolic activity of 
cells.